CG
BHVN

Cutler Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Cutler Group’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,300
Closed -$196K – 5700
2022
Q3 		$196K Sell
1,300
-7,800
-86% -$1.16M 0.01% 968
2022
Q2 		$1.32M Buy
9,100
+4,196
+86% +$536K 0.09% 266
2022
Q1 		$581K Buy
4,904
+2,996
+157% +$374K 0.03% 625
2021
Q4 		$262K Buy
1,908
+916
+92% +$116K 0.01% 1120
2021
Q3 		$137K Buy
+992
New +$124K 0.01% 1662
2021
Q2 		– Sell
-1,769
Closed -$144K – 6791
2021
Q1 		$120K Sell
1,769
-3,943
-69% -$319K 0.01% 1636
2020
Q4 		$489K Buy
5,712
+2,947
+107% +$250K 0.02% 642
2020
Q3 		$179K Buy
+2,765
New +$181K 0.01% 978
2020
Q2 		– Sell
-4,762
Closed -$253K – 5227
2020
Q1 		$162K Sell
4,762
-3,889
-45% -$178K 0.01% 1080
2019
Q4 		$470K Sell
8,651
-791
-8% -$39.2K 0.03% 468
2019
Q3 		$393K Sell
9,442
-5,884
-38% -$249K 0.04% 422
2019
Q2 		$671K Buy
15,326
+14,826
+2,965% +$836K 0.06% 283
2019
Q1 		$25K Buy
+500
New +$21.6K ﹤0.01% 1895
2018
Q4 		– Sell
-100
Closed -$3K – 5094
2018
Q3 		$3K Sell
100
-200
-67% -$7.36K ﹤0.01% 3433
2018
Q2 		$11K Sell
300
-4,759
-94% -$151K ﹤0.01% 2656
2018
Q1 		$130K Buy
+5,059
New +$151K 0.01% 1036

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Cutler Group's BHVN Position: Q4 2022 in Review

Cutler Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,300 shares — an estimated $196K sold.

Cutler Group first reported a position in BHVN in Q1 2018 and held it in 16 quarters. The position peaked at $1.32M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Cutler Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 1,300 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $196K.
  • Cutler Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 16 quarters.
  • Cutler Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.32M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.